ArticleBiology methods & protocols2025
In-silico identification of phytochemical compounds from various medicinal plants as potent HIV-1 non-nucleoside reverse transcriptase inhibitors utilizing molecular docking and molecular dynamics simulations.
Article in Biology methods & protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anti-HIV Potential ofViruses · 2026Article
- Integrated in silico and in vivo larvicidal evaluation of compounds targeting juvenile hormone for malaria vector control.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV is a global public health challenge. The Reverse Transcriptase (RT) enzyme facilitates an important step in HIV replication. Inhibition of this enzyme provides a critical target for HIV treatment. The aim of this study is to employ computational techniques to screen bioactive compounds from different medicinal plants toward identifying potent HIV-1 RT inhibitors better activity than the current ones. We conducted a literature review of HIV-1 RT inhibitors, and eighty-four (84) compounds, while target receptor (1REV) was retrieved from Protein Data Bank. The molecular docking and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) evaluations were performed using the Maestro Schrodinger software user interface. The drug-likeness and pharmacokinetic profile evaluation were carried out using SwissADME and ADMETlab3.0 web servers. Lastly, molecular dynamics simulation study was conducted using the Desmond tool of Schrodinger. The molecular docking study revealed that Rosmarinic acid (-13.265 kcal/mol), Evafirenz/standard drug (-12.175 kcal/mol), Arctigenin (-11.322 kcal/mol), Luteolin (-11.274 kcal/mol), Anolignan A (-11.157 kcal/mol), and Quercetin (-11.129 kcal/mol) can effectively bind with high affinity and low energy values to the HIV-1 RT enzyme. The relative binding free energies of Rosmarinic acid, Evafirenz, Arctigenin, Luteolin, Anolignan A, and Quercetin were -66.85, -66.53, -51.83, -49.77, -58.17, and -49.62 Δg bind, respectively. The ADMET profile of Arctigenin was similar to that of Efavirenz, and better than that of other top compounds. The molecular dynamics simulation study showed better stability of rosmarinic acid with the active site of HIV-1 NNRT than the cocrystalized ligand. Out of the top five compounds identified in this study, Rosmarinic acid, a current inhibitor of HIV-1 RT in vitro, showed the most promising prediction. However, further in vivo studies and human clinical trials are required to provide more concrete information regarding its efficacy as potent HIV-1 RT inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.